Oncology Central

Cancer drug prices in the era of healthcare reform


Several proposals in the PPACA as well as those being considered for future legislation will have a substantial impact on cancer drug prices. One such proposal in the PPACA facilitates the entry of generic competition for biological drugs (biologics). The complex nature of biologics means that generic versions are likely to be similar but not identical to the innovator drug – hence their classification as ‘biosimilars’. The introduction of biosimilars is particularly pertinent to oncology for two reasons. First, cancer therapies are set to dominate the biologics market.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.